Results 121 to 130 of about 53,685 (285)

Is levodopa toxic?

, 2004
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of
Muller, T, Jost, WH, Schwarz, J, Odin, P, Hefter, H, Hueber, R, Leenders, KL   +6 more
core   +1 more source

Digital Handwriting Reveals Motor Impairment, Dopaminergic Response, and Progression in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Digital handwriting distinguishes PD patients from healthy controls but is rarely assessed quantitatively. Objectives To evaluate digital handwriting as an objective tool to assess motor impairment, dopaminergic response, and progression in PD.
Lola Díaz‐Feliz, Marcos Faundez‐Zanuy, Andrea Gennari, Alexia Sánchez‐Reyes, Pilar Sanz‐Cartagena, José Arbelo‐González, Miguel Ángel García‐Cabezas, Pedro García‐Ruiz   +7 more
wiley   +1 more source

Dissociable Handwriting Domains in Parkinson's Disease? [PDF]

Mov Disord Clin Pract
Abstract Background Handwriting abnormalities in Parkinson's disease (PD) extend beyond classical micrographia and may involve multiple graphomotor domains with distinct clinical and mechanistic correlates. Objectives To investigate whether distinct handwriting domains demonstrate dissociable relationships with differential diagnostic performance ...
Cetin B, Comoglu S, Ulker A, Onder H.
europepmc   +2 more sources

Early‐Onset Parkinson's Disease with 22q11.2 Microdeletion and Pathogenic GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Nikolai Gil D. Reyes, Daniel G. Di Luca, Ivan Martinez‐Valbuena, Erik Boot, Maria Corral, Ryan K.C. Yuen, Connie Marras, Anthony E. Lang, Anne S. Bassett   +8 more
wiley   +1 more source

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date

, 2018
Ami B Patel, Joohi Jimenez-Shahed Department of Neurology, Baylor College of Medicine, Houston, TX, USA Abstract: Inhaled levodopa is a newly emerging therapeutic option in the treatment of “off” symptoms associated with Parkinson ...
Patel AB, Jimenez-Shahed J
core  

Acute Post‐Partum Psychosis and Dystonia Reveals Late‐Onset MPAN

Movement Disorders Clinical Practice, EarlyView.
Mathilde Lachaume, Audrey Schalk, Nadège Calmels, Christine Tranchant, Ozanne de Andrade, Fabrice Berna, Mathieu Anheim, Thomas Wirth   +7 more
wiley   +1 more source

Levodopa and Melanoma: Practical Recommendations for Parkinson's Disease—International Parkinson and Movement Disorder Society Scientific Issues Committee Viewpoint

Movement Disorders Clinical Practice, EarlyView.
Giorgia Sciacca, Inas Elsayed, Santiago Perez‐Lloret, Tiago F. Outeiro, Vivek K. Unni, Jeffery H. Kordower, Daniela Berg, Lorraine V. Kalia, on behalf of the MDS Scientific Issues Committee, Jane Alty, Alexander Balck, Daniela Berg, Per Borghammer, Inas Elsayed, Yue Huang, Walaa Kamel Elsayed, Jeffrey Kordower, Alexander Lehn, Michele Matarazzo, Tiago Mestre, Tiago Outeiro, Gian Pal, Santiago Perez Lloret, Roopa Rajan, Sephira Ryman, Giorgia Sciacca, Per Svenningsson, Lorraine Kalia   +27 more
wiley   +1 more source

A Multimodal Nomogram Predicting the Risk of Cognitive Impairment in Parkinson Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Cognitive impairment is the most consequential non‐motor complication of Parkinson's disease (PD), yet no validated tool integrates multimodal data to predict individualized risk trajectories. Objectives The aim is to develop and internally validate a time‐to‐event nomogram for predicting 5‐year risk of cognitive impairment in PD ...
Ahmed Negida
wiley   +1 more source

Clinical Outcome Assessments in Movement Disorders: A Scoping Review of Current Rating Scales and Future Needs Beyond Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COA) are essential for evaluating symptom severity, treatment response, and disease progression in movement disorders. As clinical knowledge evolves, it is necessary to ensure COAs continued relevance and validity.
Panagiota Tsitsi, Evita Papathoma, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Alberto J. Espay, Tiago A. Mestre, Alvaro Sanchez Ferro, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

A Portrait of Anxiety and Depression in Parkinson's Disease: Prevalence, Clinical Correlates, and Treatment Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms (NMS), specifically anxiety and depression are major drivers of disability in Parkinson's disease (PD). Prevalence estimates remain inconsistent because of differences in population samples, diagnostic criteria, and symptom overlap, contributing to underdiagnosis and undertreatment.
Marshall Schmidt, Kelly E. Lyons, Rajesh Pahwa, Yvonne Colgrove, Wen Liu   +4 more
wiley   +1 more source